Relevant bibliographies by topics / Pharmaceutical biotechnology. Protein drugs Antibiotics

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters

Academic literature on the topic 'Pharmaceutical biotechnology. Protein drugs Antibiotics'

Author: Grafiati
Published: 4 June 2021
Last updated: 8 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical biotechnology. Protein drugs Antibiotics.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmaceutical biotechnology. Protein drugs Antibiotics"

1

Al Bratty, Mohammed, Ayman Q. Hakami, Hatim A. Masmali, Md Shamsher Alam, Hassan A. Alhazmi, Neelaveni Thangavel, Asim Najmi, Sivakumar S. Moni, and Anzarul Haque. "The Spectrum of Thiazolidinediones against Respiratory Tract Pathogenic Bacteria: An In Vitro and In Silico Approach." Current Pharmaceutical Biotechnology 21, no. 14 (December 7, 2020): 1457–69. http://dx.doi.org/10.2174/1389201021666200618161210.

Full text
Abstract:
Background and Objectives: Drug design strategies to develop novel broad-spectrum antibacterial agents for the treatment of respiratory tract infections that can combat bacterial resistance are currently gaining momentum. 2,4-thiazolidinedione is a structural scaffold that contains pharmacophores similar to β-lactam and non- β-lactam antibiotics. The objective of the study was to synthesize newer 3,5-Disubstituted-2,4-Thiazolidinediones (DTZDs) and subject them to in vitro antibacterial screening against bacterial pathogens. Also, we performed in silico docking of selected compounds to penicillin-binding proteins and beta-lactamases. Methods: Intermediate Schiff bases were prepared by the reaction between 2,4-thiazolidinedione and an appropriate aldehyde followed by acylation of the ring nitrogen with 3-brompropanoyl chloride resulting in DTZDs. Minimum inhibitory concentrations were determined against few bacteria infecting the respiratory tract by the broth tube dilution method. Zones of inhibitions against the bacteria were also determined using agar well diffusion technique. Molecular docking of the compounds to all types of Penicillin-Binding Proteins (PBPs) and β-lactamases was also carried out. Results: Compounds DTZD12 and DTZD16 exhibited broad-spectrum antibacterial activity. The minimum inhibitory concentrations of the compounds were 175μg/100μL. Measurements of the zones of inhibitions indicated that compound DTZD12 was more active than DZTD16. E. coli was the most susceptible organism. Docking results established that both the compounds were able to interact with PBPs and β-lactamases through strong hydrogen bonds, especially the unique interaction with active serine residue of the PBP for inhibition of cell wall synthesis. Conclusion: DTZD12 and DTZD16 can be developed into antibacterial drugs for respiratory tract infections to oppose bacterial resistance, or can also be used as leads for repurposing the existing 2,4- thiazolidinediones.
APA, Harvard, Vancouver, ISO, and other styles
2

Klein, Ronald D., and Timothy G. Geary. "Recombinant Microorganisms as Tools for High Throughput Screening for Nonantibiotic Compounds." Journal of Biomolecular Screening 2, no. 1 (February 1997): 41–49. http://dx.doi.org/10.1177/108705719700200108.

Full text
Abstract:
Microorganisms were among the first tools used for the discovery of biologically active compounds. Their utility reached a zenith during the era of antibiotic development in the 1950s and 1960s, then declined. Subsequently, a substantial role for microorganisms in the pharmaceutical industry developed with the realization that microbial fermentations were intriguing sources of nonantibiotic natural products. From recombinant DNA technology emerged another important role for microorganisms in pharmaceutical research: the expression of heterologous proteins for therapeutic products or for in vitro high throughput screens (HTSs). Recent developments in cloning, genetics, and expression systems have opened up new applications for recombinant microorganisms in screening for nonantibiotic compounds in HTSs. These screens employ microorganisms that depend upon the function of a heterologous protein for survival under defined nutritional conditions. Compounds that specifically target the heterologous protein can be identified by measuring viability of the microorganism under different nutrient selection. Advantages of this approach include a built-in selection for target selectivity, an easily measured end point that can be used for a multitude of different targets, and compatibility with automation required for HTSs. Mechanism-based HTSs using recombinant microorganisms can also address drug targets that are not readily approachable in other HTS formats, including certain enzymes; ion channels and transporters; and protein::protein, protein::DNA, and protein::RNA interactions.
APA, Harvard, Vancouver, ISO, and other styles
3

Winther, Tabita, and Lene Oddershede. "Effect of Antibiotics and Antimicrobial Peptides on Single Protein Motility." Current Pharmaceutical Biotechnology 10, no. 5 (August 1, 2009): 486–93. http://dx.doi.org/10.2174/138920109788922083.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tabassum Samanta, Mahonaz, and Sadia Noor. "PROSPECTS AND CHALLENGES OF PHARMACEUTICAL BIOTECHNOLOGY." International Journal of Advanced Research 9, no. 01 (January 31, 2021): 709–29. http://dx.doi.org/10.21474/ijar01/12349.

Full text
Abstract:
Biotechnology is a broad area of biology, involving the use of living systems and organisms to develop products. Depending on the tools and applications, it often overlaps with related scientific fields. In the late 20th and early 21st centuries, biotechnology has expanded to include new and diverse sciences, such as genomics, recombinant gene techniques, applied immunology, and development of pharmaceutical therapies and diagnostic tests. Biotechnology has also led to the development of antibiotics. Biotechnology has applications in four major industrial areas, including health care (medical), crop production and agriculture, non-food (industrial) uses of crops and other products and environmental uses. In medicine, modern biotechnology has many applications in areas such as pharmaceutical drug discoveries and production, pharmacogenomics, and genetic testing. Pharmaceutical biotechnology is a relatively new and growing field in which the principles of biotechnology are applied to the development of drugs. A majority of therapeutic drugs in the current market are bio formulations, such as antibodies, nucleic acid products and vaccines. Such bio formulations are developed through several stages that include: understanding the principles underlying health and disease the fundamental molecular mechanisms governing the function of related biomolecules synthesis and purification of the molecules determining the product shelf life, stability, toxicity and immunogenicity drug delivery systems patenting and clinical trials. This review article describes the purpose of biotechnology in pharmaceutical industry, particularly pharmaceutical biotechnology along with its prospects and challenges.
APA, Harvard, Vancouver, ISO, and other styles
5

Cobos-Puc, Luis, Raúl Rodríguez-Herrera, Juan C. Cano-Cabrera, Hilda Aguayo-Morales, Sonia Y. Silva-Belmares, Adriana C. F. Gallegos, and José L. M. Hernández. "Classical and New Pharmaceutical Uses of Bacterial Penicillin G Acylase." Current Pharmaceutical Biotechnology 21, no. 4 (March 25, 2020): 287–97. http://dx.doi.org/10.2174/1389201020666191111151642.

Full text
Abstract:
Background: β-lactam antibiotics are the most used worldwide for the treatment of bacterial infections. The consumption of these classes of drugs is high, and it is increasing around the world. To date, the best way to produce them is using penicillin G Acylase (PGA) as a biocatalyst. Objective: This manuscript offers an overview of the most recent advances in the current tools to improve the activity of the PGA and its pharmaceutical application. Results: Several microorganisms produce PGA, but some bacterial strains represent the primary source of this enzyme. The activity of bacterial PGA depends on its adequate expression and carbon or nitrogen source, as well as a specific pH or temperature depending on the nature of the PGA. Additionally, the PGA activity can be enhanced by immobilizing it to a solid support to recycle it for a prolonged time. Likewise, PGAs more stable and with higher activity are obtained from bacterial hosts genetically modified. Conclusion: PGA is used to produce b-lactam antibiotics. However, this enzyme has pharmaceutical potential to be used to obtain critical molecules for the synthesis of anti-tumor, antiplatelet, antiemetic, antidepressive, anti-retroviral, antioxidant, and antimutagenic drugs.
APA, Harvard, Vancouver, ISO, and other styles
6

Potocki, Leszek, Bernadetta Oklejewicz, Ewelina Kuna, Ewa Szpyrka, Magdalena Duda, and Janusz Zuczek. "Application of Green Algal Planktochlorella nurekis Biomasses to Modulate Growth of Selected Microbial Species." Molecules 26, no. 13 (July 1, 2021): 4038. http://dx.doi.org/10.3390/molecules26134038.

Full text
Abstract:
As microalgae are producers of proteins, lipids, polysaccharides, pigments, vitamins and unique secondary metabolites, microalgal biotechnology has gained attention in recent decades. Microalgae can be used for biomass production and to obtain biotechnologically important products. Here, we present the application of a method of producing a natural, biologically active composite obtained from unicellular microalgae of the genus Planktochlorella sp. as a modulator of the growth of microorganisms that can be used in the cosmetics and pharmaceutical industries by exploiting the phenomenon of photo-reprogramming of metabolism. The combination of red and blue light allows the collection of biomass with unique biochemical profiles, especially fatty acid composition (Patent Application P.429620). The ethanolic and water extracts of algae biomass inhibited the growth of a number of pathogenic bacteria, namely Enterococcus faecalis, Staphylococcus aureus PCM 458, Streptococcus pyogenes PCM 2318, Pseudomonas aeruginosa, Escherichia coli PCM 2209 and Candida albicans ATCC 14053. The algal biocomposite obtained according to our procedure can be used also as a prebiotic supplement. The presented technology may allow the limitation of the use of antibiotics and environmentally harmful chemicals commonly used in preparations against Enterococcus faecalis, Staphylococcus aureus, Streptococcus pyogenes, Pseudomonas aeruginosa, Escherichia coli or Candida spp.
APA, Harvard, Vancouver, ISO, and other styles
7

Messaoudi, Abdelmonaem, Manel Zoghlami, Zarrin Basharat, and Najla Sadfi-Zouaoui. "Identification of a Potential Inhibitor Targeting MurC Ligase of the Drug Resistant Pseudomonas aeruginosa Strain through Structure-Based Virtual Screening Approach and In Vitro Assay." Current Pharmaceutical Biotechnology 20, no. 14 (November 15, 2019): 1203–12. http://dx.doi.org/10.2174/1389201020666190719123133.

Full text
Abstract:
Background & Objective: Pseudomonas aeruginosa shows resistance to a large number of antibiotics, including carbapenems and third generation cephalosporin. According to the World Health Organization global report published in February 2017, Pseudomonas aeruginosa is on the priority list among resistant bacteria, for which new antibiotics are urgently needed. Peptidoglycan serves as a good target for the discovery of novel antimicrobial drugs. Methods: Biosynthesis of peptidoglycan is a multi-step process involving four mur enzymes. Among these enzymes, UDP-N-acetylmuramate-L-alanine ligase (MurC) is considered to be an excellent target for the design of new classes of antimicrobial inhibitors in gram-negative bacteria. Results: In this study, a homology model of Pseudomonas aeruginosa MurC ligase was generated and used for virtual screening of chemical compounds from the ZINC Database. The best screened inhibitor i.e. N, N-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazole-5-sulfonamide was then validated experimentally through inhibition assay. Conclusion: The presented results based on combined computational and in vitro analysis open up new horizons for the development of novel antimicrobials against this pathogen.
APA, Harvard, Vancouver, ISO, and other styles
8

Osa-Andrews, Bremansu, Kee Tan, Angelina Sampson, and Surtaj Iram. "Development of Novel Intramolecular FRET-Based ABC Transporter Biosensors to Identify New Substrates and Modulators." Pharmaceutics 10, no. 4 (October 13, 2018): 186. http://dx.doi.org/10.3390/pharmaceutics10040186.

Full text
Abstract:
Multidrug resistance protein 1 (MRP1) can efflux a wide variety of molecules including toxic chemicals, drugs, and their derivatives out of cells. Substrates of MRP1 include anti-cancer agents, antibiotics, anti-virals, anti-human immunodeficiency virus (HIV), and many other drugs. To identify novel substrates and modulators of MRP1 by exploiting intramolecular fluorescence resonance energy transfer (FRET), we genetically engineered six different two-color MRP1 proteins by changing green fluorescent protein (GFP) insertion sites, while keeping the red fluorescent protein (RFP) at the C-terminal of MRP1. Four of six recombinant proteins showed normal expression, localization, and transport activity. We quantified intramolecular FRET using ensemble fluorescence spectroscopy in response to binding of known substrate or ATP alone, substrate/ATP, and trapping of the transporter in closed conformation by vanadate. Recombinant MRP1 proteins GR-881, GR-888, and GR-905 exhibited reproducible and higher FRET changes under all tested conditions and are very promising for use as MRP1 biosensors. Furthermore, we used GR-881 to screen 40 novel anti-cancer drugs and identified 10 hits that potentially directly interact with MRP1 and could be substrates or modulators. Profiling of drug libraries for interaction with MRP1 can provide very useful information to improve the efficacy and reduce the toxicity of various therapies.
APA, Harvard, Vancouver, ISO, and other styles
9

Keskar, Mrudul R., and Ravin M. Jugade. "Spectrophotometric Investigations of Macrolide Antibiotics: A Brief Review." Analytical Chemistry Insights 10 (January 2015): ACI.S31857. http://dx.doi.org/10.4137/aci.s31857.

Full text
Abstract:
Macrolides, one of the most commonly used class of antibiotics, are a group of drugs produced by Streptomyces species. They belong to the polyketide class of natural products. Their activity is due to the presence of a large macrolide lactone ring with deoxy sugar moieties. They are protein synthesis inhibitors and broad-spectrum antibiotics, active against both gram-positive and gram-negative bacteria. Different analytical techniques have been reported for the determination of macrolides such as chromatographic methods, flow injection methods, spectrofluorometric methods, spectrophotometric methods, and capillary electrophoresis methods. Among these methods, spectrophotometric methods are sensitive and cost effective for the analysis of various antibiotics in pharmaceutical formulations as well as biological samples. This article reviews different spectrophotometric methods for the determination of macrolide antibiotics.
APA, Harvard, Vancouver, ISO, and other styles
10

Salmaso, Stefano, Sara Bersani, Alessandra Semenzato, and Paolo Caliceti. "Nanotechnologies in Protein Delivery." Journal of Nanoscience and Nanotechnology 6, no. 9 (September 1, 2006): 2736–53. http://dx.doi.org/10.1166/jnn.2006.456.

Full text
Abstract:
The growth rate for biotech drugs, namely proteins, peptides, and oligonucleotides, is dictated by the parallel progresses in biotechnology and nanotechnology. Actually, biotechnology techniques have expanded enormously the arsenal of therapeutically useful peptides and proteins making these products of primary interest for future pharmaceutical market. Nevertheless, the exploitation of protein and peptide drugs is strictly related to the development of innovative delivery systems which should provide for controlled, prolonged, or targeted delivery, improved stability during storage and delivery, reduced adverse effects, increased bioavailability, improved patient compliance and allow for administration through the desired route and cope with cost-containment therapeutic protocols. Colloidal formulations ideally possess the physicochemical and biopharmaceutical requisites for protein delivery. Pharmaceutical nanotechnology is a tool of techniques applied to design, develop and produce these systems. It involves the investigation of innovative materials and production procedures for preparation of a variety of nanosized dosage forms, which range from solid nanoparticles to soluble bioconjugates. The research and development of innovative tailor made protein delivery systems, which must be designed according to the drug candidate pharmacological and physicochemical properties, is one of the primary aim of modern pharmaceutical technology. Therefore, as an unmet need exists for technologies that combine innovative drug delivery solutions, a close un-prejudicial interaction between academic and industrial researchers as well as business thought leaders is required.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pharmaceutical biotechnology. Protein drugs Antibiotics"

1

Fung, Ho Ki. "Synthesis and development of manufacturing processes for biopharmaceuticals /." View Abstract or Full-Text, 2003. http://library.ust.hk/cgi/db/thesis.pl?BIEN%202003%20FUNG.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Pharmaceutical biotechnology. Protein drugs Antibiotics"

1

Rotheim, Philip. Bioengineered protein drugs: Enzymes. Norwalk, CT: Business Communications Co., 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rotheim, Philip. Bioengineered protein drugs: Antibodies, blood proteins. Norwalk, CT: Business Communications Co., 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rotheim, Philip. Bioengineered protein drugs: Cytokines/growth factors, peptide hormones. Norwalk, CT: Business Communications Co., 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Approaches to the conformational analysis of biopharmaceuticals. Boca Raton: CRC Press/Taylor & Francis, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Niazi, Sarfaraz. Handbook of biogeneric therapeutic proteins: Regulatory, manufacturing, testing, and patent issues. Boca Raton: Taylor & Francis, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

(Editor), Steve L. Nail, and Michael J. Akers (Editor), eds. Development and Manufacture of Protein Pharmaceuticals (Pharmaceutical Biotechnology) (Pharmaceutical Biotechnology). Springer, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

(Editor), Lynda M. Sanders, and R. Wayne Hendren (Editor), eds. Protein Delivery: Physical Systems (Pharmaceutical Biotechnology). Springer, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

(Editor), Rodney Pearlman, and Y. John Wang (Editor), eds. Formulation, Characterization, and Stability of Protein Drugs: Case Histories (Pharmaceutical Biotechnology) (Pharmaceutical Biotechnology). Springer Verlag, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

(Editor), Henry R. Costantino, and Michael J. Pikal (Editor), eds. Lyophilization of Biopharmaceuticals (Biotechnology: Pharmaceutical Aspects). American Association of Pharmaceuticals Scientists, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

(Editor), John F. Carpenter, and Mark C. Manning (Editor), eds. Rational Design of Stable Protein Formulations: Theory and Practice (Pharmaceutical Biotechnology). Springer, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Pharmaceutical biotechnology. Protein drugs Antibiotics"

1

Working, Peter K. "Potential Effects of Antibody Induction by Protein Drugs." In Pharmaceutical Biotechnology, 73–92. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4899-2329-5_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Winter, Gerhard, and Julia Myschik. "Formulation Strategies for Recombinant Protein and Related Biotech Drugs." In Pharmaceutical Biotechnology, 235–56. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2012. http://dx.doi.org/10.1002/9783527632909.ch10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Meibohm, Bernd, and Rene Braeckman. "Pharmacokinetics and Pharmacodynamics of Peptide and Protein Drugs." In Pharmaceutical Biotechnology, 95–123. CRC Press, 2007. http://dx.doi.org/10.3109/9781420044386-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

"Excipients for Protein Drugs." In Excipient Development for Pharmaceutical, Biotechnology, and Drug Delivery Systems, 311–52. CRC Press, 2006. http://dx.doi.org/10.1201/9781420004137-20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kosky, Andrew, Eva Kras, Arnold McAuley, Richard Remmele, and Manmohan Singh. "Excipients for Protein Drugs." In Excipient Development for Pharmaceutical, Biotechnology, and Drug Delivery Systems, 291–331. CRC Press, 2006. http://dx.doi.org/10.1201/9781420004137.ch17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kamboj, Sweta, Rohit Kamboj, Shikha Kamboj, Rohit Dutt, Reeva Chabbra, and Priyanka Kriplani. "Role of Anti-Viral Drugs in Combating SARS-CoV-2." In Biotechnology to Combat COVID-19 [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.99599.

Full text
Abstract:
Viruses are the eventual assertion of parasitism, they not only take nutriments from the host cell, apart from that they direct its metabolic machinery to amalgamate novel virus particle and to diminish the ability of flu viruses to reproduce in an individual antiviral drugs are used. When used as directed, antiviral drugs may help to lessen the duration of flu symptoms and may reduce the severity of common flu symptoms. Antiviral drugs are the class of drugs which comes under the antimicrobials, and that also accommodates the larger group i.e. of antibiotics. They are broad-spectrum in nature and can be effective against a wide range of viruses. They can be used as a single drug as well as in combination of drugs. Antiviral drugs are dissimilar from the antibiotics, they do not demolish their target pathogen ideally they obstruct development of pathogen. To the greatest extent antiviral drugs currently accessible are delineate to deal with herpes viruses, covid-19, HIV, the hepatitis b and c viruses herpes simplex, small pox, picornavirus and influenza a and b viruses etc. Scientists are searching to drag out the range of antiviral to the other families of pathogens. They mainly act by inhibiting the attachment of viruses on cells, prevent genetic reproduction of virus, prevent viral protein production and vital for production of virus. The emanation of antiviral is generally the outcome about an appreciably expanded skills or proficiency of the generative, microscopic and atomic activity of organisms, allowing biomedical analyst to acknowledge the structure, mechanism of action and activity of viruses, significant progress within the procedure for come across the current drugs. Coronavirus 2019 (COVID 19) is highly infectious disease triggered by SARS-CoV-2 (severe acute respiratory syndrome) coronavirus 2 causing nearly 2.9 million deaths worldwide. With the emergence of SARS-CoV-2, the repurposing of antiviral drugs has come into picture.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pharmaceutical biotechnology. Protein drugs Antibiotics' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography